Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

Rebecca A Shatsky^{1

2}, Hemali Batra-Sharma^{1

2}, Teresa Helsten^{1

2}, Richard B Schwab^{1

2}, Emily I Pittman¹, Minya Pu¹, Elizabeth Weihe³, Emanuela M Ghia^{1

4}, Laura Z Rassenti^{1

4}, Alfredo Molinolo¹, Betty Cabrera⁵, James B Breitmeyer⁶, George F Widhopf Ii^{2

4}, Karen Messer^{1

7}, Catriona Jamieson^{1

2

5

8}, Thomas J Kipps^{1

4}, Barbara A Parker^{9

10}

Affiliations

¹ Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.
² Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA.
³ Department of Radiology, University of California San Diego, La Jolla, San Diego, CA, USA.
⁴ Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA, USA.
⁵ University of California San Diego California Institute for Regenerative Medicine Alpha Clinic, La Jolla, San Diego, CA, USA.
⁶ Oncternal Therapeutics, Inc., San Diego, CA, USA.
⁷ Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, San Diego, CA, USA.
⁸ Sanford Stem Cell Institute, University of California San Diego, La Jolla, San Diego, CA, USA.
⁹ Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA. baparker@health.ucsd.edu.
¹⁰ Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA. baparker@health.ucsd.edu.

Published Erratum

Rebecca A Shatsky et al. Breast Cancer Res. 2024.

. 2024 Mar 13;26(1):46.

doi: 10.1186/s13058-024-01805-w.

¹ Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.
² Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA.
³ Department of Radiology, University of California San Diego, La Jolla, San Diego, CA, USA.
⁴ Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA, USA.
⁵ University of California San Diego California Institute for Regenerative Medicine Alpha Clinic, La Jolla, San Diego, CA, USA.
⁶ Oncternal Therapeutics, Inc., San Diego, CA, USA.
⁷ Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, San Diego, CA, USA.
⁸ Sanford Stem Cell Institute, University of California San Diego, La Jolla, San Diego, CA, USA.
⁹ Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA. baparker@health.ucsd.edu.
¹⁰ Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA. baparker@health.ucsd.edu.

No abstract available

Erratum for

A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
Shatsky RA, Batra-Sharma H, Helsten T, Schwab RB, Pittman EI, Pu M, Weihe E, Ghia EM, Rassenti LZ, Molinolo A, Cabrera B, Breitmeyer JB, Widhopf GF 2nd, Messer K, Jamieson C, Kipps TJ, Parker BA. Shatsky RA, et al. Breast Cancer Res. 2024 Feb 26;26(1):32. doi: 10.1186/s13058-024-01782-0. Breast Cancer Res. 2024. PMID: 38408999 Free PMC article. Clinical Trial.

1. Shatsky RA, Batra-Sharma H, Helsten T, et al. A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer. Breast Cancer Res. 2024;26:32. doi: 10.1186/s13058-024-01782-0. - DOI - PMC - PubMed